Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 2/20 | 0.38 |
| ▸ | EDNRA | P25101 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18261063 | 0.83 | MTNR1A (0.37) | NPC1RAB9ALMNAHTTCYP1A2 | |
| SCHEMBL25357694 | 0.79 | KDM4E (0.45) | NPC1RAB9ALMNAHTTCYP1A2 | |
| SCHEMBL18289991 | 0.79 | CA12 (0.49) | HTTNPSR1 | |
| SCHEMBL18886356 | 0.76 | SMN1; SMN2 (0.40) | NPC1RAB9ALMNAHTTSMN1; SMN2 | |
| SCHEMBL18886473 | 0.76 | SMN1; SMN2 (0.40) | NPC1RAB9ALMNAHTTSMN1; SMN2 | |
| SCHEMBL16585292 | 0.75 | NPC1 (0.42) | NPC1RAB9ALMNAHTTCYP1A2 | |
| SCHEMBL2886185 | 0.75 | RAB9A (0.36) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL24042179 | 0.74 | CHRNB2 (0.43) | EDNRBEDNRA | |
| SCHEMBL23804030 | 0.74 | DRD4 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1MTNR1A | |
| SCHEMBL18990622 | 0.74 | HDAC3 (0.41) | NPC1RAB9AALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022053541-A1 | COMPOUNDS FOR USE AS APPETITE SUPPRESSANT | ERACAL THERAPEUTICS LTD. (CH) | 2022-03-17 | — | — | WO | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-3555088-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109647-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| US-20180127378-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| EP-3302471-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | Eisai R&D Management Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-9796683-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-10-24 | — | — | US | disclosed |
| WO-2016196337-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196346-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| US-20160347717-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | BRCA1, ESR2, ESR1 | NPC1 421/4885RAB9A 1518/4885LMNA 3864/4885 |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | NFE2L2, KEAP1, NQO1 | NPC1 907/4885RAB9A 1599/4885LMNA 2553/4885 |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | NPC1 907/4885RAB9A 1599/4885LMNA 2553/4885 |
| US-20160347717-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | NPC1 421/4885RAB9A 1518/4885LMNA 3864/4885 |
| US-20180127378-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | NPC1 421/4885RAB9A 1518/4885LMNA 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.